Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 4/20 | 0.70 |
| ▸ | PIM2 | Q9P1W9 | 4/20 | 0.70 |
| ▸ | CSNK2B | P67870 | 3/20 | 0.70 |
| ▸ | CSNK2A1 | P68400 | 3/20 | 0.70 |
| ▸ | LCK | P06239 | 15/20 | 0.57 |
| ▸ | LYN | P07948 | 1/20 | 0.41 |
| ▸ | BTK | Q06187 | 1/20 | 0.41 |
| ▸ | FLT3 | P36888 | 1/20 | 0.40 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.40 |
| ▸ | BAD | Q92934 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13056970 | 0.88 | PIM1 (0.68) | PIM1PIM2CSNK2BCSNK2A1LCK | |
| SCHEMBL13056974 | 0.76 | PIM1 (0.68) | PIM1PIM2CSNK2BCSNK2A1LCK | |
| SCHEMBL10136946 | 0.75 | PIM1 (0.69) | PIM1PIM2FLT3PIM3BAD | |
| SCHEMBL13057012 | 0.74 | LCK (0.63) | PIM1PIM2CSNK2BCSNK2A1LCK | |
| SCHEMBL7981902 | 0.74 | LCK (1.00) | PIM1PIM2CSNK2BCSNK2A1LCK | |
| SCHEMBL13057014 | 0.73 | LCK (0.61) | PIM1PIM2CSNK2BCSNK2A1LCK | |
| SCHEMBL12768784 | 0.73 | PIM1 (0.52) | PIM1PIM2CSNK2BCSNK2A1FLT3 | |
| SCHEMBL13056975 | 0.73 | CSNK2B (0.65) | PIM1PIM2CSNK2BCSNK2A1LCK | |
| SCHEMBL13056987 | 0.72 | PIM1 (0.52) | PIM1PIM2CSNK2BCSNK2A1FLT3 | |
| SCHEMBL12768827 | 0.71 | PIM1 (0.59) | PIM1PIM2CSNK2BCSNK2A1FLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298302-A1 | NOVEL PROTEIN KINASE MODULATORS | SENHWA BIOSCIENCES, INC. (TW) | 2010-11-25 | — | — | US | disclosed |
| US-20100298302-A1 | NOVEL PROTEIN KINASE MODULATORS | SENHWA BIOSCIENCES, INC. (TW) | 2010-11-25 | — | — | US | disclosed |
| WO-2010135571-A1 | NOVEL PROTEIN KINASE MODULATORS | CYLENE PHARMACEUTICALS, INC. (US) | 2010-11-25 | — | — | WO | disclosed |
| WO-2010135571-A1 | NOVEL PROTEIN KINASE MODULATORS | CYLENE PHARMACEUTICALS, INC. (US) | 2010-11-25 | — | — | WO | disclosed |
| US-20100298302-A1 | NOVEL PROTEIN KINASE MODULATORS | SENHWA BIOSCIENCES, INC. (TW) | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298302-A1 | NOVEL PROTEIN KINASE MODULATORS | PIM2, PIM1, PIM3 | PIM1 2/4885PIM2 1/4885CSNK2B 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.